Form 4: Leap Therapeutics Chief Scientific Officer Jason Baum Departs, Ceases SEC Reporting Obligations
Officer Departure Filing
Jason Baum, Chief Scientific Officer of Leap Therapeutics, Inc., is no longer serving in his role effective June 30, 2025, and will cease Section 16 reporting obligations.
Summary
- Jason Baum has ceased serving as the Chief Scientific Officer of Leap Therapeutics, Inc. (LPTX).
- The effective date of his departure from the role is June 30, 2025.
- As a result of his departure, Jason Baum is no longer subject to Section 16 of the Securities Exchange Act of 1934.
- He will no longer be required to report transactions in Leap Therapeutics, Inc. equity securities on Form 4 or Form 5.
Sentiment
Score: 5
Explanation: The document is a factual report of a personnel change and cessation of reporting obligations, providing no qualitative assessment or forward-looking financial information to indicate positive or negative sentiment.
Future Outlook
The document indicates that the reporting person, Jason Baum, will no longer be subject to Section 16 reporting requirements for transactions in Leap Therapeutics, Inc. equity securities following his departure.
Industry Context
The departure of a Chief Scientific Officer is a significant event in the biotechnology and pharmaceutical industry, as the CSO typically plays a crucial role in guiding research and development pipelines, which are central to a company's long-term value creation. Such changes can signal strategic shifts or leadership transitions within the company's scientific direction.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Chief Scientific Officer | Jason Baum | Not specified in document | 06/30/2025 | No longer serving |
Stakeholder Impact
- Shareholders may be impacted by the change in leadership within the scientific division, potentially influencing future research and development strategies and pipeline progress.
- Employees within the scientific and R&D departments may experience changes in leadership and strategic direction.
Next Steps
- Jason Baum will no longer file Form 4 or Form 5 for transactions in Leap Therapeutics, Inc. equity securities.
Key Dates
| Date | Description |
|---|---|
| 06/30/2025 | Effective date of Jason Baum's cessation as Chief Scientific Officer of Leap Therapeutics, Inc. |
| 07/01/2025 | Date the Form 4 was signed by Douglas E. Onsi, as attorney-in-fact for Jason Baum. |
Keywords
Leap Therapeutics, LPTX, Jason Baum, Chief Scientific Officer, CSO, Executive Departure, SEC Form 4, Section 16, Corporate Governance, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.